Concurrent BRAF/MEK Inhibitors in BRAF V600–Mutant High-Grade Primary Brain Tumors

Karisa C. Schreck, MD, PhD; Andrew Guajardo, MD; Doris D.M. Lin, MD, PhD; Charles G. Eberhart, MD, PhD; and Stuart A. Grossman, MD

Abstract

BRAF V600 mutations are being identified in patients with primary brain tumors more often as molecular testing becomes widely available. Targeted treatment with BRAF inhibitors has been attempted in individual cases with some responses, whereas others showed no response or developed resistance. Preclinical work suggests that gliomas could be more responsive to the concurrent use of BRAF and MEK inhibition for MAP kinase pathway suppression. This report presents 2 cases of malignant brain tumors with BRAF V600E mutations that were resistant to radiation and temozolomide, and reports on their response to targeted treatment with the BRAF and MEK inhibitors dabrafenib and trametinib. One patient with an anaplastic pleomorphic xanthoastrocytoma experienced a partial response for 14 months, demonstrated by progressive tumor shrinkage and clinical improvement; however, this was followed by clinical and radiographic progression. The patient with glioblastoma continued to have stable disease after 16 months of treatment. These cases are encouraging in a disease that urgently needs new treatments. Further work is necessary to understand response rates, duration, and survival in primary brain tumors.

J Natl Compr Canc Netw 2018;16(4):343–347


As tumor profiling becomes more widespread, targetable mutations are being found in patients with brain tumors. One of these mutations, BRAF V600, allows this protein kinase to act as an oncogene activating the ERK signaling pathway, which leads to cell proliferation and survival. BRAF V600E is the most common mutation, although there are others that occur less frequently (V600K/D/R). BRAF-specific inhibitors have been developed and are effective in melanoma, with approximately 50% of metastatic melanomas showing response. Unfortunately, tumor resistance often emerges through several different mechanisms in an average of 5 to 7 months. Attempts have been made to bypass this resistance by blocking MEK, which is just downstream of BRAF, thereby making it more difficult for tumors to escape inhibition. However, if a BRAF inhibitor is followed by a MEK inhibitor at progression, there is only marginal improvement in survival (1.8 months). More recently, the upfront combination of BRAF and MEK inhibitors has shown improved progression-free survival compared with monotherapy and is FDA-approved for advanced-stage melanoma.

BRAF V600 mutations have been discovered in a variety of adult and pediatric brain tumors, including pleomorphic xanthoastrocytomas (PXAs) (50%–65%), gangliogliomas (20%–70%), pilocytic astrocytomas (9%–10%), low-grade gliomas (5%–15%), and adult glioblastomas (1%–5%). These mutations are less common in typical adult high-grade tumors, such as glioblastoma. However, they are relatively enriched in the epithelioid subtype of glioblastoma, and possibly in low-grade astrocytomas as well (5%–15%). There have been a few cas-

*Department of Neurology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; †Department of Pathology, Johns Hopkins University; ‡Department of Radiology and Radiological Science, Johns Hopkins Hospital; and ††The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland.

The authors have disclosed that they have no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors.

Correspondence: Karisa C. Schreck, MD, PhD, Department of Neurology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Suite 1M16, CRB II, 1550 Orleans Street, Baltimore, MD 21287.

Email: kso1t1@jhmi.edu

Submitted July 5, 2017; accepted for publication October 18, 2017.
es in which targeted treatment with BRAF inhibitors has been successfully attempted, but resistance emerges in a few months, similar to what has been seen in melanoma and other tumor types. The emergence of resistance over time has been reproduced in preclinical glioma models, although these models have also shown that dual inhibition with BRAF and MEK inhibitors can prevent resistance.

This report presents 2 cases of treatment-refractory high-grade primary brain tumors treated with dual BRAF and MEK inhibitors: 1 anaplastic PXA and 1 epithelioid glioblastoma. Both cases showed clinical and radiographic response to treatment for ≥14 months, highlighting the potential utility of BRAF-targeted therapy in high-grade astrocytomas refractory to standard treatment with radiation and temozolomide.

Approval was obtained from both patients to submit their clinical and imaging data for a case report, in agreement with the Johns Hopkins Institution Institutional Review Board requirements.

**Case Reports**

**Case 1**

A 16-year-old man presented with focal seizures and a left temporal lobe mass in 1998, which was observed until 2002 when he underwent surgery, and pathology results showed PXA. He underwent a second surgery in 2004 after demonstrating progression, with pathology still showing typical microscopic features of PXA, WHO grade II (Figure 1A), and then experienced stable disease for the next 10 years. In 2014, at age 32 years, radiographic and clinical progression prompted his third surgery. Microscopic examination revealed an increased number of mitotic figures, resulting in a diagnosis of anaplastic PXA (Figure 1B). Molecular studies showed a BRAF V600E mutation and no IDH1 mutation by immunohistochemistry. His postoperative course was complicated by infection and placement of a ventriculoperitoneal shunt. He was treated with radiation and concurrent temozolomide, followed by 6 cycles of adjuvant temozolomide. He experienced progression 4 months later and received 1 cycle of salvage BCNU with no signs of tumor response. In October 2015, he underwent another resection of his growing tumor for presumed progression, with pathology showing persistent anaplastic PXA morphology with variable pleomorphism, eosinophilic granular bodies, and frequent mitoses (Figure 1C). In the setting of progression, he began receiving repeat irradiation. However, this was discontinued abruptly after only 4 of 20 planned treatments when he experienced an acute left internal capsule stroke. In January 2016, he began therapy with dabrafenib at 150 mg twice daily and trametinib at 2 mg daily, with a Karnofsky performance status (KPS) of 50 and an ECOG performance status (PS) of 3.

Treatment was complicated by fevers and a rash that responded to steroids. The steroids were titrated to symptoms, with a maximum dosage of 4 mg/d, and
were stopped 8 months after treatment initiation. His clinical condition and MRI scans steadily improved, and he became functionally independent. In February 2017, he presented to the hospital leaking cerebrospinal fluid through his nose and was admitted with pneumocephalus. This was the result of tumor regression, which had previously eroded through the subarachnoid space and bone. He was treated surgically with an autologous fascial graft to the skull base and a mesh cranioplasty. A small amount of residual tumor was harvested at that time and pathology was notable for scattered cells consistent with PXA and inconspicuous mitotic activity. The tissue continued to show the BRAF V600E mutation on molecular testing.

He continued to do well on BRAF/MEK inhibitors, with a KPS of 70, for 14 months after initiating therapy. He also continued to show steadily decreasing volume of enhancing tumor on MRI over the course of treatment (Figure 2A, B). Tumor volumes were quantified using the lesion segmentation function in the CARESTREAM PACS system (Carestream Health, Inc.). Unfortunately, his routine MRI scan performed 16 months after treatment initiation showed signs of tumor progression and BRAF/MEK inhibition was discontinued. Detailed molecular testing on his tissue at that time showed the BRAF V600E mutation continued to be expressed and that there were no additional mutations in BRAF. Additionally, there were missense mutations of unclear significance in FLT4, NOTCH1, and TSC2, but no known resistance mechanisms.

Case 2
A 23-year-old woman presented in November 2008 with hemiplegia, diplopia, and sensory changes and was diagnosed with left frontal epithelioid glioblastoma. The tumor was glial fibrillary acidic protein–positive, but IDH, MGMT, and BRAF testing were not performed at that time. She underwent a gross total resection followed by radiation with concurrent temozolomide. One month later, she received an additional stereotactic boost of 25 Gy and adjuvant temozolomide for 12 cycles. In September 2010, she underwent surgery for suspected disease progression based on imaging, but pathology showed gliosis. In November 2014, she had a new local nodule resected and 2.5 Gliadel wafers (Eisai Inc., Woodcliff, NJ) were placed. Histopathology of the recurrent epithelioid glioblastoma demonstrated abundant eosinophilic cytoplasm, frequent mitotic activity, vascular proliferation, and necrosis. Molecular testing at that time revealed a BRAF V600E mutation and no IDH1/2 mutations. She was observed until there was evidence of radiographic tumor progression on 2 serial MRI scans 1 month apart. In January 2016, she was started on dabrafenib at 150 mg twice daily and trametinib at 2 mg daily; her KPS was 70 and ECOG PS was 2.

In the first few weeks of starting treatment, she experienced fevers, hypotension, and meningismus,

![Figure 2](image_url)
causing her to stop the medications. She restarted dabrafenib at a reduced dose of 100 mg twice daily, trametinib at 2 mg daily, and dexamethasone at 2 mg daily. She tolerated this regimen well, but became symptomatic if dexamethasone was decreased. At the time of writing, she has completed 16 months of therapy and has shown stable disease on MRI per RANO criteria (Figure 3) and has stable functional status. She continues on 2 mg daily of dexamethasone.

Discussion
This manuscript reports on 2 people with BRAF V600–mutated primary brain tumors treated as adults with concurrent BRAF and MEK inhibitors. In both of these cases, patients received ≥1 rounds of standard chemotherapy and radiation, and experienced disease progression before initiating treatment with BRAF and MEK inhibitors. In response to treatment with BRAF/MEK inhibitors, the patients had either stable disease or partial response for ≥14 months. This is unusual in high-grade primary brain tumors, which are relentlessly progressive once they begin to grow and do not generally undergo spontaneous regression or senescence. It is also notable because standard-of-care second- or third-line treatments have limited efficacy.

It is interesting that the first case showed progressive tumor shrinkage over the course of 14 months. This is different from what is typically seen in melanoma, even brain metastases, where most of the response occurs in the first few weeks of treatment. This observation suggests potentially different pharmacokinetics in this tumor type (PXA), or a differential dependence on the ERK signaling pathway compared with other tumor types. Alternatively, it may be due to less drug accumulation within the tumor and brain parenchyma, because preclinical models suggest both dabrafenib and trametinib have limited central nervous system penetration due to active drug efflux.

It is unclear whether BRAF V600–mutated primary brain tumors respond differentially to BRAF or MEK monotherapy versus a combination. Preclinical work has shown that BRAF inhibitors transiently decrease ERK signaling in glioma cell lines. Coinhibition with BRAF and MEK inhibitors pro-

Table 1. Published Reports of BRAF-Directed Therapy in Adults

<table>
<thead>
<tr>
<th>Age, y/Sex</th>
<th>Histology</th>
<th>Prior Rx</th>
<th>BRAF Rx</th>
<th>Time on Rx</th>
<th>Best Outcome</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>34/F</td>
<td>PXA</td>
<td>RT, TMZ, PCV</td>
<td>Vemurafenib</td>
<td>4 mo</td>
<td>SD</td>
</tr>
<tr>
<td>2</td>
<td>47/F</td>
<td>PXA</td>
<td>RT, TMZ, PCV</td>
<td>Vemurafenib</td>
<td>10 mo</td>
<td>PR</td>
</tr>
<tr>
<td>3</td>
<td>53/M</td>
<td>PXA</td>
<td>RT+TMZ, PCV</td>
<td>Vemurafenib</td>
<td>10 mo</td>
<td>PR</td>
</tr>
<tr>
<td>4</td>
<td>43/M</td>
<td>Anaplastic PXA</td>
<td>RT+TMZ, PCV</td>
<td>Vemurafenib</td>
<td>6 mo</td>
<td>Progression</td>
</tr>
<tr>
<td>5</td>
<td>26/M</td>
<td>Epithelioid GBM</td>
<td>None</td>
<td>Vemurafenib</td>
<td>1 wk</td>
<td>PR</td>
</tr>
<tr>
<td>6</td>
<td>39/M</td>
<td>Anaplastic PXA</td>
<td>RT</td>
<td>Vemurafenib</td>
<td>2 mo</td>
<td>CR</td>
</tr>
<tr>
<td>7</td>
<td>41/M</td>
<td>Anaplastic PXA</td>
<td>TMZ, RT+TMZ</td>
<td>Vemurafenib</td>
<td>3 mo</td>
<td>PR</td>
</tr>
<tr>
<td>8</td>
<td>35/F</td>
<td>PXA</td>
<td>None</td>
<td>Dabrafenib</td>
<td>3 mo</td>
<td>PR</td>
</tr>
<tr>
<td>9</td>
<td>25/M</td>
<td>HGG from ganglioglioma</td>
<td>RT+TMZ with adjuvant TMZ X 4</td>
<td>Dabrafenib, Optune (Novocure)</td>
<td>≥24 mo</td>
<td>CR</td>
</tr>
<tr>
<td>10</td>
<td>21/F</td>
<td>Anaplastic PXA</td>
<td>RT, vemurafenib</td>
<td>Dabrafenib</td>
<td>≥16 mo</td>
<td>CR</td>
</tr>
<tr>
<td>11</td>
<td>35/M</td>
<td>Anaplastic PXA</td>
<td>RT+TMZ, BCNU</td>
<td>Dabrafenib, trametinib</td>
<td>≥14 mo</td>
<td>PR</td>
</tr>
<tr>
<td>12</td>
<td>32/F</td>
<td>Epithelioid GBM</td>
<td>RT+TMZ, Gliadel</td>
<td>Dabrafenib, trametinib</td>
<td>≥14 mo</td>
<td>PR</td>
</tr>
</tbody>
</table>

Abbreviations: CR, complete response; F, female; GBM, glioblastoma; HGG, high-grade glioma; M, male; PCV, procarbazine/lomustine/vincristine; PR, partial response; PXA, pleomorphic xanthoastrocytoma; RT, radiation therapy; Rx, treatment; SD, stable disease; TMZ, temozolomide.
vides a more durable response in vitro and in vivo. However, to date, case reports in adults with primary brain tumors have only examined BRAF inhibition, resulting in a mix of response and progression (Table 1). Whether adding an MEK inhibitor would change the clinical course is unknown. To answer this question, 2 clinical trials evaluating the activity of dabrafenib and trametinib in pediatric patients with recurrent BRAF V600–mutated low- or high-grade gliomas (ClinicalTrials.gov identifiers: NCT02124772 and NCT02684058, respectively) are open or planned to open shortly.

Notably, the effect of a BRAF V600 mutation on the natural history of brain tumors in adults remains to be determined. One retrospective review of young adults aged 17 to 35 years with glioblastomas found a more favorable overall survival among those with BRAF mutations than those without. Another retrospective review of PXAs also found a more favorable overall survival associated with BRAF V600 mutation than without; however, this could not be controlled for tumor grade because more of the mutations were seen in grade II than grade III PXA. Regardless, in the cases reported herein, the tumors were progressive despite aggressive treatment with radiation and chemotherapy, necessitating a new treatment strategy. Dual BRAF/MEK inhibition precipitated tumor response or stable disease for more than a year, making this an interesting potential treatment for other patients with similar tumors.

Conclusions

The cases described in this report demonstrate that targeting the BRAF V600 mutation with dual BRAF/MEK inhibition in recurrent primary brain tumors may produce a durable response. Further studies are needed to determine formal response rates, response durations, the impact of this therapy on survival, and the entry of these agents into brain parenchyma.

References